阿戈美拉汀联合认知行为疗法治疗首发抑郁症的临床疗效分析  

Clinical efficacy of agomelatine combined with cognitive behavioral therapy in the treatment of first-episode depression

作　　者：梁其生 叶健[1] LIANG Qi-sheng;YE Jian(Department of Medical Psychology,Zhaoqing Third People's Hospital,Zhaoqin 526000,China)

机构地区：[1]肇庆市第三人民医院医学心理科,广东肇庆526000

出　　处：《中国处方药》2022年第2期124-125,共2页Journal of China Prescription Drug

摘　　要：目的探讨阿戈美拉汀联合认知行为疗法治疗首发抑郁症的临床疗效。方法选取2019年2月~2021年2月收治的150例首发抑郁症患者,随机分为观察组与对照组,每组75例。对照组患者接受阿戈美拉汀治疗,观察组患者接受阿戈美拉汀联合认知行为疗法干预。疗程结束后,分别记录两组患者的HAMD-17量表评分、综合治疗效果,并比较不良反应发生情况。结果治疗前,两组患者HAMD评分差异无统计学意义(P>0.05),具有可比性。接受不同治疗后,两组患者HAMD评分均较治疗前降低(P<0.05)。组间比较显示,治疗后观察组HAMD评分低于对照组患者(P<0.05)。观察组患者治疗总有效率为80.00%,高于对照组患者治疗总有效率50.67%(P<0.05)。对所有患者进行至少2周随访,两组患者用药后不良反应发生率差异无统计学意义(P>0.05)。结论阿戈美拉汀联合认知行为疗法治疗首发抑郁症能够有效改善患者HAMD-17量表评分以及抑郁状态,具有较好的综合疗效,且不会增加不良反应的发生风险,具有一定的安全性。Objective To investigate the clinical efficacy of agomelatine combined with cognitive behavioral therapy in the treatment of first-episode depression.Methods 150 patients with first-episode depression from February 2019 to February 2021 were randomly divided into the observation group and the control group,75 cases in each group.The control group was treated with agomelatine,while the observation group was treated with agomelatine combined with cognitive behavioral therapy.After the course of treatment,the HAMD-17 score and comprehensive treatment effect of the two groups were recorded,and the incidence of adverse reactions was compared.Results Before treatment,there was no significant difference in HAMD score between the two groups(P>0.05),which was comparable.After receiving different treatments,HAMD scores of the two groups decreased before treatment(P<0.05).The HAMD score of the observation group was lower than that of the control group after treatment(P<0.05).The total effective rate of the observation group was 80.00%,which was higher than 50.67%of the control group(P<0.05).All patients were followed up for at least 2 weeks.There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Agomelatine combined with cognitive behavioral therapy in the treatment of first-episode depression can effectively improve the HAMD-17 scale score and depression state of patients,with good comprehensive curative effect,and will not increase the risk of adverse reactions,and has certain safety.

关 键 词：阿戈美拉汀 认知行为疗法 抑郁症 安全性 

分 类 号：R749.4[医药卫生—神经病学与精神病学]